School of Medicine
Showing 1-100 of 119 Results
-
Catherine Aftandilian
Clinical Associate Professor, Pediatrics - Hematology & Oncology
Current Research and Scholarly InterestsI conduct clinical research on the prevention, early diagnosis, and treatment of infectious complications in pediatric patients with leukemia.
-
Michael Amylon
Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital, Emeritus
Current Research and Scholarly InterestsBone marrow transplantation (BMT) is a treatment modality which is being broadly applied to a growing number of disorders. Increasing success with BMT is offering improved survival to pediatric and adult patients with acute leukemia, chronic leukemia, lymphomas, and a variety of solid tumors as well as severe aplastic anemia.
-
Glaivy Batsuli, MD
Assistant Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsHemophilia is a rare inherited X-linked bleeding disorder characterized by the deficiency of blood clotting proteins factor VIII or factor IX. These individuals are at risk for spontaneous bleeds and trauma or surgery-induced bleeding. There have been remarkable advancements in the management of hemophilia to prevent these bleeding episodes and improve quality of life. However, the presence of neutralizing antibodies, called inhibitors, still dictates access to novel therapies such as factor replacement for bleed management and now FDA-approved gene therapies. The Batsuli Lab is focused on elucidating mechanisms of the immune response to blood coagulation proteins in bleeding disorders in order to develop strategies and therapeutics for inhibitor prevention and tolerance induction.
Dr. Batsuli's clinical research interests also include clinical trial participation for novel therapeutics & interventions in bleeding disorders such as hemophilia and von Willebrand disease in addition to coagulation issues & outcomes in ultra-rare bleeding disorders and sickle cell disease. -
Harvey Cohen
Deborah E. Addicott - John A. Kriewall and Elizabeth A. Haehl Family Professor of Pediatrics, Emeritus
Current Research and Scholarly InterestsMy research interests extend from hypothesis-driven studies in biochemistry and cell biology to discovery-driven interests in proteomics and systems biology to clinical treatment of acute lymphoblastic leukemia of children, and pediatric palliative care.
-
Jacquelyn Nicole Crane
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
BioDr. Jacquelyn Crane is a Clinical Assistant Professor in the Pediatric Hematology Oncology division at Lucile Packard Children’s Hospital, Stanford University School of Medicine. She received her undergraduate degree from Dartmouth College. She then conducted laboratory-based genetics research for two years in the Pauls lab at Massachusetts General Hospital. She received her medical degree from Tufts University School of Medicine and completed her pediatrics residency and pediatric hematology/oncology fellowship training at University of California Los Angeles. As a pediatric hematology & oncology fellow, she engaged in computational analysis of osteosarcoma transcriptomic data in the Graeber Lab and completed a medical education fellowship certificate program. Her primary clinical and research interests include sarcomas, Wilms tumor, and other solid tumors, cancer genomics, clinical trials and medical education. She is the associate program director of the pediatric hematology-oncology fellowship.
-
Gary Dahl
Professor of Pediatrics (Hematology/Oncology), Emeritus
Current Research and Scholarly InterestsHematology/Oncology, Phase I drug studies for childhood cancer, overcoming multidrug resistance in leukemia and solid tumors, biology and treatment of acute nonlymphocytic leukemia, early detection of central nervous system leukemia by measuring growth, factor binding proteins.
-
Heike Daldrup-Link
Professor of Radiology (General Radiology) and, by courtesy, of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsAs a physician-scientist involved in the care of pediatric patients and developing novel pediatric molecular imaging technologies, my goal is to link the fields of nanotechnology and medical imaging towards more efficient diagnoses and image-guided therapies. Our research team develops novel imaging techniques for improved cancer diagnosis, for image-guided-drug delivery and for in vivo monitoring of cell therapies in children and young adults.
-
Kara Davis
Assistant Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsChildhood cancers can be considered aberrations of normal tissue development. We are interested in understanding childhood cancers through the lens of normal development. Further, individual tumors are composed of heterogeneous cell populations, not all cells being equal in their ability to respond to treatment or to repopulate a tumor. Thus, we take single cell approach to determine populations of clinical relevance.
-
Pablo Domizi, Ph.D.
Instructor, Pediatrics - Hematology & Oncology
Current Research and Scholarly InterestsUnderstanding phenotypic flexibility in B-cell ALL and its impact on CAR-T therapy success. Integration of single cell RNA and protein expression data to build models to predict patients at risk of Antigen Loss relapse after CAR-T cell immunotherapies.
-
Charles Gawad
Associate Professor of Pediatrics (Hematology/Oncology)
BioOur lab works at the interface of biotechnology, computational biology, cellular biology, and clinical medicine to develop and apply new tools for characterizing genetic variation across single cells within a tissue with unparalleled sensitivity and accuracy. We are focused on applying these technologies to study cancer clonal evolution while patients are undergoing treatment with the aim of identifying cancer clonotypes that are associated with resistance to specific drugs so as to better understand and predict treatment response. We are also applying these methods to understand how more virulent pathogens emerge from a population of bacteria or viruses with an emphasis on developing a deeper understanding of how antibiotic resistance develops.
-
Bertil Glader
Stanford Medicine Professor of Pediatric Hematology/Oncology and Professor, by courtesy, of Pathology
Current Research and Scholarly InterestsHematology/Oncology, biology, and treatment of bone marrow failure disorders, hereditary coagulation disorders-clinical trials.
-
Anju Goyal
Masters Student in Community Health and Prevention Research, admitted Autumn 2022
Fellow in Pediatrics - Hematology & Oncology
Resident in Pediatrics - Hematology & OncologyBioDr. Anju Goyal is a pediatric hematology oncology fellow physician at Stanford University School of Medicine. She received her undergraduate degree from the University of Chicago. She then served as an AmeriCorps member with City Year Chicago, fostering her dual interests in community advocacy and education. She went on to receive her medical degree from the David Geffen School of Medicine at the University of California, Los Angeles and to complete her pediatrics residency at Stanford University School of Medicine.
During her research time as a pediatric hematology oncology fellow, Dr. Goyal has pursued a Master's degree in the Community Health and Prevention Program at Stanford University. She sought this additional research training to learn how to parter effectively with communities to achieve health equity. Specifically, her primary research project has utilized the principles of community based participatory research to partner with a local organization, Jacob's Heart, and to understand the financial burden of childhood cancer for Latinx families. Additionally, she has honed a skill set in medical education and is conducting research on how to promote well being for pediatric hematology oncology fellows. -
Michael Jeng
Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsResearch interests focus on: 1) histiocytic disorders, such as Langerhans cell histiocytosis (LCH) and hemophagocytic lymphohistiocytosis (HLH), and 2) vascular anomalies and malformations.
-
Norman J. Lacayo, MD
Associate Professor of Pediatrics (Hematology and Oncology)
Current Research and Scholarly InterestsPediatric Hematology/Oncology, Phase I drug studies for refractory and relapsed leukemia; genomic studies, biologic risk-stratification and treatment of acute myeloid leukemia; prediction or induction response and risk of relapse using phosphoproteomics in childhood AML; novel MRD techniques in childhood ALL.
-
Christine Shyrue Lai
Affiliate, Dean's Office Operations - Dean Other
Fellow in Pediatrics - Hematology & OncologyBioDr. Christine Lai is a Pediatric Hematology Oncology Fellow in the Bass Center at Lucile Packard Children's Hospital. Prior to coming to Stanford, she trained in pediatric residency at Northwell Alexandra Cohen Children's Hospital in New Hyde Park, NY and attended medical school at New York University. Her current research interests are cancer immunotherapy and cancer glycobiology. She currently works in Professor Carolyn Bertozzi's lab and sees patients in the Bass Center Clinic.
-
Michael Link
Lydia J. Lee Professor of Pediatric Cancer
Current Research and Scholarly InterestsHematology/Oncology, treatment of sarcomas of bone and soft tissue, biology of acute lymphoblastic leukemias, treatment of non-Hodgkin's lymphoma and Hodgkin's disease.
-
Y. Lucy Liu, MD, PhD
Senior Research Scientist, Pediatrics - Hematology/Oncology
Current Role at StanfordSenior Research Scientist
-
Clara Lo
Clinical Associate Professor, Pediatrics - Hematology & Oncology
Current Research and Scholarly InterestsResearch interests include:
Biomarkers and targeted therapy in pediatric immune thrombocytopenia
Transfusion-related iron overload
Hemophilia and other rare bleeding disorders
Thrombophilia -
Adrienne H. Long, MD, PhD
Instructor, Pediatrics - Hematology & Oncology
BioAdrienne H. Long, MD, PhD is an instructor in the Division of Pediatric Hematology and Oncology at the Lucile Packard Children's Hospital at Stanford. Dr. Long attend Northwestern University, where she earned both her BS in biomedical engineering and her MD. Determined to help develop novel treatments for pediatric cancer patients, she took time during medical school to pursue a PhD at the National Institutes of Health (NIH), where she helped advance CAR T cell therapies with Dr. Crystal Mackall. Her influential thesis work was the first to identify T cell exhaustion as a critical factor limiting efficacy of CAR therapies (Long et al., Nature Medicine, 2015), and also identified novel methods to enhance CAR therapies for pediatric solid tumor patients (Long/Highfill et al., Cancer Immunology Research, 2016). Dr. Long went on to complete her pediatrics residency training at Boston Children’s Hospital, where she continued her research in cancer immunology with Dr. Nicholas Haining – this time focusing on strategies to enhance antigen presentation to augment checkpoint blockade (Long et al. Keystone Symposium on Cancer Immunotherapy, 2019). She completed her pediatric oncology fellowship at Stanford, and remains dedicated to a career as a physician-scientist focused on developing novel immunotherapies for children with cancer. She is currently conducting her post-doctoral research with Dr. Mark Davis, studying how thymic selection, designed to prevent auto-immunity, may also inhibit antitumor immunity in children.
-
Crystal Mackall
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Current Research and Scholarly InterestsRecent clinical studies, by us and others, have demonstrated that genetically engineered T cells can eradicate cancers resistant to all other therapies. We are identifying new targets for these therapeutics, exploring pathways of resistance to current cell therapies and creating next generation platforms to overcome therapeutic resistance. We have discovered novel insights into the biology of human T cell exhaustion and developed approaches to prevent and reverse this phenomenon.
-
Robbie Majzner
Assistant Professor - University Medical Line, Pediatrics - Hematology & Oncology
BioRobbie Majzner is an Assistant Professor of Pediatrics in the Division of Hematology and Oncology. After graduating with a BA from Columbia University, Dr. Majzner attended Harvard Medical School, where he developed an interest in pediatric oncology. He completed his residency training in pediatrics at New York Presbyterian-Columbia and fellowship training in pediatric hematology-oncology at Johns Hopkins and the National Cancer Institute. During his fellowship, he cared for some of the first pediatric patients to receive CD19 chimeric antigen receptor (CAR) T cells, children with B cell acute lymphoblastic leukemia (B-ALL) who often had no other therapeutic option. Witnessing the success of CAR T cells in these patients drove Dr. Majzner to the laboratory, where he focuses on extending the use of CAR T cells to solid tumors. He has generated and optimized novel receptors to recognize antigens over-expressed on pediatric solid tumors such as GD2 (Mount/Majzner et al., Nature Medicine, 2018) B7-H3 (Majzner et al., Clinical Cancer Research, 2019), and ALK (Walker/Majzner et al., Molecular Therapy, 2017). Current work focuses on imparting multi-specificity to CAR T cells and optimizing these receptors to enhance their efficacy when the amount of target (antigen density) is limiting (Majzner et al., Cancer Discovery, 2020). By drawing on state of the art bioengineering techniques, the Majzner Laboratory focuses on enhancing the potency and specificity of CAR T cells for children with cancer.
Clinically, Dr. Majzner cares for all patients with neuroblastoma at the Lucile Packard Children's Hospital and has a specific interest in bringing novel immunotherapies to clinical trials for these patients and those with other solid tumors. He is board certified in pediatrics and pediatric hematology-oncology. -
Neyssa Marina
Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital, Emerita
Current Research and Scholarly InterestsGerm cell tumors and bone sarcomas.
-
Anupama Narla
Assistant Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsMy research interests are to study the pathophysiology of ribosomopathies and to translate these insights into the work-up and management of pediatric bone marrow failure syndromes.
-
Aluya Oseghale, PhD
Postdoctoral Scholar, Stem Cell Transplantation
BioMy primary goal is to develop an independent research career in hematology. As an African from a family background afflicted by hereditary hematologic disorders, I have longed to be part of research efforts to develop better treatments for blood diseases. My doctoral research focused on sickle cell disease where I conducted a preclinical investigation of a novel derivative of butyrate as a drug candidate for ameliorating the complications of the illness (Oseghale AR et al. Blood Cells Mol Dis. 2019 Jul 9;79:102345). My current focus as a postdoctoral scholar, in the Porteus laboratory, is to use CRISPR/Cas9 for genomic modification of human primary cells for curative therapeutic applications. A major aim of my project is to develop an automated closed system for the manufacturing of CRISPR/Cas9-engineered chimeric antigen receptor-expressing (CAR) T cells.
-
Allison Pribnow
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
Current Research and Scholarly InterestsSolid Tumors, Bone Sarcomas, Global Oncology, Health Disparities
-
Sneha Ramakrishna
Assistant Professor of Pediatrics (Hematology/Oncology)
BioSneha Ramakrishna obtained her B. A. from the University of Chicago and her M.D. from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. In medical school, through the Howard Hughes Medical Research Scholar Award, she joined Dr. Crystal Mackall’s laboratory, where she designed and developed various GD2 CAR-Ts and tested them in preclinical models. During her residency training in Pediatrics at the Children’s Hospital of Philadelphia, she cared for some of the first patients treated with CD19 CAR T cells, learning the power of this therapy first-hand. During her fellowship in Pediatric Hematology/Oncology at the Johns Hopkins/National Cancer Institute combined program, she worked with Dr. Terry Fry. She evaluated the mechanism of CD22 CAR T cell relapse in patients by developing an antigen escape model and establishing a deeper understanding of the effects of antigen density on CAR-T phenotype, expansion, and persistence (Fry…Ramakrishna…Mackall Nat Med, 2018; Ramakrishna, et al., Clinical Cancer Research, 2019). Since arriving at Stanford, Dr. Ramakrishna leads an interdisciplinary team that designs, develops, and successfully implements a robust correlative science platform for our novel CAR-T therapies. Analyzing patient samples from our first-in-human GD2 CAR-T trial (NCT04196413) treating a universally fatal cancer, diffuse midline glioma (DMG), we identified that intracerebroventricular CAR-T administration correlates with enhanced pro-inflammatory cytokines and reduced immunosuppressive cell populations in cerebrospinal fluid as compared to intravenous CAR-T administration (Majzner*, Ramakrishna*, et al., Nature 2022 *co-first authors). Her research program evaluates unique sets of patient samples using novel single-cell immune profiling to identify the drivers of CAR-T success or failure. Building on these findings, her team will assess approaches to enhance CAR-T efficacy and translate these findings to the clinic.
Clinically, Dr. Ramakrishna cares for children with solid tumors and treats hematologic, solid, and brain tumor pediatric patients with CAR T cell therapies in the Cancer Cellular Therapies program. -
Rameshwar (Ram) Rao MD PhD
Postdoctoral Medical Fellow, Hematology-Oncology
Fellow in Pediatrics - Hematology & OncologyBioMy scientific training spans over a decade of published research in the fields of vascularized bone tissue engineering, biomineralization, gene therapy, and spectral ultrasound. I earned my BS from UC Davis and MS/PhD in Biomedical Engineering at the University of Michigan. I have aimed to form highly collaborative and multidisciplinary research groups at each level of training. This work has resulted in 21 publications, award-winning manuscripts, and multiple national conference research awards. My successful research career began during my undergraduate studies where my work in Prof. Kent Leach’s lab resulted in 3 publications and the Department of Biomedical Engineering Outstanding Undergraduate Research Award. My graduate thesis under the guidance of Prof. Jan Stegemann resulted in 12 publications (7 as first author) in high quality, peer-reviewed journals in the fields of engineering and biotechnology. My graduate studies were funded by an NIH T32 Training grant and the NSF Graduate Research Fellowship. My graduate work culminated in the 2013 Outstanding PhD Research Award from the Society for Biomaterials (SFB) and the 2013 Outstanding Student Award from the Tissue Engineering and Regenerative Medicine Society (TERMIS). Recognizing the gap in translation of bioengineering research into clinical practice, I opted to pursue an MD at the University of Michigan to become the physician-scientist that identifies clinical problems, engineers the solution, and delivers it back to the patient to advance treatments and improve survival outcomes. My success continued through medical school with 4 clinical research manuscripts and Graduation with Distinction in Research, awarded to 10% of the class.
In the next phase of my training, I will complete my fellowship in Pediatric Hematology/Oncology at Stanford through the Accelerated Research Pathway by the American Board of Pediatrics. Prof. Sarah Heilshorn, Associate Chair of Materials Science at Stanford, will be my primary research and career development mentor. Together, we have designed an innovative approach targeting the extracellular matrix to improve survival outcomes in pediatric osteosarcoma. -
Raya Saab
Lindhard Family Professor of Pediatric Cancer Biology
BioOur laboratory focuses on investigating molecular mechanisms of oncogene-induced tumorigenesis and tumor suppressor pathways, and oncogenic signaling in the pediatric solid tumor rhabdomyosarcoma. Our earlier work identified the tumor suppressors p53 and p18Ink4c as inhibitors of Cyclin D1-driven tumorigenesis in a pineoblastoma model, through senescence induction, and highlighted distinct roles for the the RB and p53 pathways in induction and maintenance of oncogene-induced senescence. We also identified CDK2 as a potential target for inducing senescence in premalignant lesions to inhibit tumor progression.
Our current focus is on studying oncogenic signaling and tumor suppression in the childhood tumor rhabdomyosarcoma, to identify key mediators of invasion and metastasis, which is the most common cause of treatment failure clinically. We use preclinical in vitro and in vivo models, including murine and human cell lines, and mouse models of disease.
We have recently uncovered a paracrine role for rhabdomyosarcoma-secreted exosomes in impacting biology of stromal cells. Rhabdomyosarcoma-derived exosomes carry specific miRNA cargo that imparts an invasive and migratory phenotype on normal recipient fibroblasts, and proteomic analysis revealed specific and unique pathways relevant to the two different molecular rhabdomyosarcoma subtypes that are driven by distinct oncogenic pathways. We identified that the driver oncogene in fusion-positive rhabdomyosarcoma, PAX3-FOXO1, modulates exosome cargo to promote invasion, migration, and angiogenic properties, and identified specific microRNA and protein cargo acting as effectors of PAX3-FOXO1 exosome-mediated signaling, including modulation of oxidative stress response and cell survival signaling.
Our ongoing work is focused on interrogating specific paracrine signaling pathways and molecular mechanisms of metastatic disease progression in rhabdomyosarcoma, for potential therapeutic targeting. -
Julien Sage
Elaine and John Chambers Professor of Pediatric Cancer and Professor of Genetics
Current Research and Scholarly InterestsWe investigate the mechanisms by which normal cells become tumor cells, and we combine genetics, genomics, and proteomics approaches to investigate the differences between the proliferative response in response to injury and the hyperproliferative phenotype of cancer cells and to identify novel therapeutic targets in cancer cells.
-
Kathleen M. Sakamoto
Shelagh Galligan Professor in the School of Medicine
Current Research and Scholarly InterestsMy research focuses on the molecular pathways that regulate normal and aberrant blood cell development, including acute leukemia and bone marrow failure syndromes. We are also studying novel drugs for treatment of cancer.
-
Liora Schultz
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
BioI am currently postdoctoral research fellow pursuing immunotherapy research in the oncology department at Stanford University. My clinical training as a pediatric hematology oncology fellow at Memorial Sloan Kettering Cancer Center highlighted the desperate need for novel therapeutic options for a subtype of aggressive pediatric leukemia, Acute Myeloid Leukemia (AML). Despite our best standard of care for AML, long term survival rates range from 50-60% with an unacceptably high relapse rate of 40%. The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. As the field of CAR therapy rapidly advances, novel methods to optimize this therapeutic modality are imperative. To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. Consolidating my clinical and research experiences within highly academic institutes allows me to synthesize my pursuit of scientific rigor and commitment to the field of oncology, with a mission to achieve productive research and translatable results.
-
Mona D. Shah, MD, MBA
Adjunct Clinical Associate Professor, Pediatrics - Hematology & Oncology
BioMona is a pediatric hematologist-oncologist, who earned her MD degree at the University of Maryland in 2001. She completed both her categorical pediatric and global health residencies in 2004, followed by a pediatric hematology-oncology fellowship in 2007. She earned her MS in Clinical Investigation as part of the Clinical Scientist Training Program at Baylor College of Medicine in 2011, and more recently, completed an Executive MBA at Rice University’s Jones School of Business in 2018.
Mona was an Associate Professor at Baylor College of Medicine (2007 - 2020) in both Pediatrics and Medicine, local site PI on a number of pediatric hemostasis/thrombosis clinical trials, and spent 10 years as an Associate Medical Director of clinical operations, quality, and safety at Texas Children’s Hospital, Houston, TX.
Mona joined Genentech (a member of Roche Group)’s Rare Blood Disorders Franchise (Product Development - Oncology-Hematology) in February 2020, now as Lead Medical Director, and currently serves as Medical Monitor for the COMMUTE-a and COMMUTE-p Phase III clinical trials (crovalimab in atypical hemolytic uremic syndrome, aHUS). She is also engaged with the Renal Franchise (I2O) in developing crovalimab in Lupus Nephritis (Phase I & II clinical trials in development), and with Human Factors/Pediatric Formulations Working Group on autoinjector devices and oral formulations. Since May 2022, Mona is spending 25% of her time with Early Development Safety (EDS) on a one year rotation. She is based in South San Francisco, CA, and will be working closely with both EDS gRED (Oncology and OMNI) teams.
Mona has kept a bucket list since she was 7 years old (keeps growing): Running wild bouldering/rock climbing as a child in the Shenandoah/Blue Ridge Mountains, swimming with dolphins/piranhas in the Amazon, climbing inside a volcano caldera in Iceland, snorkeling the Great Barrier Reef ... have passport/will travel!
Since July 2022, she has joined Stanford University School of Medicine, as an Adjunct Clinical Associate Professor in the Department of Pediatrics, Division of Hematology-Oncology. Mona enjoys free time in her new home base near San Francisco, where she hosts her visiting parents, friends, and extended family.